Mechanistic Clinical Trial Evaluating the Role of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) in the Antidepressant Mechanism of Cognitive Behavioral Therapy for Insomnia (CBT-I)
Status: Recruiting
Location: See location...
Intervention Type: Drug, Behavioral
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
This is mechanistic clinical trial that evaluates the role of one of the glutamate receptors (mGluR5) in cognitive behavioral therapy for insomnia (CBT-I) as a common pathway in improving sleep and depression.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• capacity to provide informed consent,
• at least 18 years of age
• good physical health and absence of significant medical conditions,
• diagnosis of major depressive disorder (MDD) with current major depressive episode as per DSM-5 criteria
• Montgomery-Åsberg Depression Rating Scale (MADRS) score \> 29 (at least moderate depression),
• uniform range of sleep latencies up to 128 minutes.
Locations
United States
New York
Stony Brook University: Dept of Psychiatry
RECRUITING
Stony Brook
Contact Information
Primary
Wendy Zhang
Wendy.Zhang@stonybrookmedicine.edu
(631)-638-2053
Backup
Christine DeLorenzo, PhD
christine.delorenzo@stonybrookmedicine.edu
(631) 638-1523
Time Frame
Start Date: 2025-08-01
Estimated Completion Date: 2030-03-31
Participants
Target number of participants: 42
Treatments
Experimental: Cognitive Behavioral Therapy for Insomnia Treatment Arm
Cognitive Behavioral Therapy for Insomnia (CBT-I) will be delivered through an online program, Sleep Healthy Using The Internet (SHUTi).
Related Therapeutic Areas
Sponsors
Leads: Stony Brook University
Collaborators: National Institute of Mental Health (NIMH), National Institutes of Health (NIH)